Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer.
Pernin V, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Bollet M, Vago NA, Dendale R, Campana F, Fourquet A, Kirova YM. Pernin V, et al. Among authors: gobillion a. Br J Radiol. 2015 Apr;88(1048):20140800. doi: 10.1259/bjr.20140800. Epub 2015 Feb 3. Br J Radiol. 2015. PMID: 25645108 Free PMC article. Clinical Trial.
Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation.
Clément-Zhao A, Tanguy ML, Cottu P, De La Lande B, Bontemps P, Lemanski C, Baumann P, Savignoni A, Levy C, Peignaux K, Reynaud-Bougnoux A, Gobillion A, Kirova Y. Clément-Zhao A, et al. Among authors: gobillion a. PLoS One. 2019 Aug 30;14(8):e0221816. doi: 10.1371/journal.pone.0221816. eCollection 2019. PLoS One. 2019. PMID: 31469859 Free PMC article.
Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study.
Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, de la Lande B, Baumann P, Missohou F, Lévy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Pernin V, Kirova Y. Dautruche A, et al. Among authors: gobillion a. Cancer Radiother. 2018 May;22(3):222-228. doi: 10.1016/j.canrad.2017.10.004. Epub 2018 Apr 9. Cancer Radiother. 2018. PMID: 29650388
High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.
Anna F, Goyard S, Lalanne AI, Nevo F, Gransagne M, Souque P, Louis D, Gillon V, Turbiez I, Bidard FC, Gobillion A, Savignoni A, Guillot-Delost M, Dejardin F, Dufour E, Petres S, Richard-Le Goff O, Choucha Z, Helynck O, Janin YL, Escriou N, Charneau P, Perez F, Rose T, Lantz O. Anna F, et al. Among authors: gobillion a. Eur J Immunol. 2021 Jan;51(1):180-190. doi: 10.1002/eji.202049058. Epub 2020 Dec 23. Eur J Immunol. 2021. PMID: 33259646 Free PMC article.